Intellia Therapeutics Names Graeme Bell Chief Financial Officer
13 Décembre 2016 - 3:20PM
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome
editing company focused on developing potentially curative
therapeutics using CRISPR/Cas9 technology, has appointed Graeme
Bell as its Chief Financial Officer. Mr. Bell succeeds Sapna
Srivastava, Ph.D., who is transitioning to a senior advisory role
within Intellia.
Mr. Bell joins Intellia from his role as Chief Financial Officer
at Anacor Pharmaceuticals, Inc., a publicly traded
biopharmaceutical company acquired by Pfizer, Inc. in June 2016. At
Anacor, he led the finance, human resources, business development,
IT, and facilities functions. Prior to Anacor, Mr. Bell spent more
than 20 years at Merck & Co, Inc., where he held numerous
finance and accounting senior-level positions including: CFO of
U.S. operations, Controller, Global Pharmaceutical Franchises, CFO
United Kingdom subsidiary, and head of investor relations. He is a
Fellow of the Institute of Management Accountants with an MBA from
the University of Durham, UK.
Mr. Bell will relocate to Intellia’s headquarters in Cambridge,
Massachusetts, overseeing all financial functions including
financial planning and analysis, financial reporting, treasury,
tax, accounting, and finance. Additionally, Mr. Bell will be
responsible for investor relations.
Dr. Srivastava has decided to transition from the Chief
Financial and Strategy Officer role to a senior advisor primarily
due to her personal commitments in New York City. Dr. Srivastava
joined Intellia in April 2015, and played an integral role in
helping start up Intellia’s financial operations and strategic
direction, the Series B private funding, and the initial public
offering. Dr. Srivastava is committed to ensuring a smooth
transition of her responsibilities to Mr. Bell. At the
conclusion of her advisory role, Dr. Srivastava will transition
from Intellia.
“I want to thank Sapna for her significant contributions to
ensuring that Intellia’s business strategy and public offering were
successful,” said Chief Executive Officer and Founder Nessan
Bermingham, Ph.D. “We welcome Graeme to his new role as he joins us
for the next phase of growth in our company. We are excited about
his extensive financial and operational experience and existing
relationships with the investment community.”
About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company,
focused on the development of proprietary, potentially curative
therapeutics using the CRISPR/Cas9 system. Intellia believes the
CRISPR/Cas9 technology has the potential to transform medicine by
permanently editing disease-associated genes in the human body with
a single treatment course. Our combination of deep scientific,
technical and clinical development experience, along with our
leading intellectual property portfolio, puts us in a unique
position to unlock broad therapeutic applications of the
CRISPR/Cas9 technology and create a new class of therapeutic
products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at
intelliatx.com; Follow us on Twitter @intelliatweets.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995. These forward looking statements include, but are not limited
to, statements regarding our growth as a company and the
anticipated contribution of executives to our operations and
progress. Any forward-looking statements in this press release are
based on management's current expectations of future events and are
subject to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those set
forth in or implied by such forward-looking statements. These
risks and uncertainties include, but are not limited to, the risk
that any one or more of our product candidates will not be
successfully developed and commercialized, the risk of cessation or
delay of any of the ongoing or planned clinical trials and/or our
development of our product candidates, the risk that the results of
previously conducted studies involving similar product candidates
will not be repeated or observed in ongoing or future studies
involving current product candidates, the risk that our
collaboration with Novartis or Regeneron will not
continue or will not be successful, risks related to the
competitive landscape, and risks related to our ability to protect
and maintain our intellectual property position. For a discussion
of other risks and uncertainties, and other important factors, any
of which could cause our actual results to differ from those
contained in the forward-looking statements, see the section
entitled "Risk Factors" in our most recent quarterly report on Form
10-Q filed with the Securities and Exchange Commission, as well as
discussions of potential risks, uncertainties, and other important
factors in our subsequent filings with the Securities and
Exchange Commission. All information in this press release is
as of the date of the release, and Intellia Therapeutics undertakes
no duty to update this information unless required by law.
Intellia Contacts:
Media:
Jennifer Mound Smoter
Chief External Affairs & Communications Officer
+1 857-706-1071
jenn.smoter@intelliatx.com
Investors:
John Graziano
Trout Group
+ 1 646-378-2942
jgraziano@troutgroup.com
Chad Rubin
Trout Group
+ 1 646-378-2947
crubin@troutgroup.com
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024